AVTR vs. REGN: Avantor vs. Regeneron Pharmaceuticals Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while REGN is classified in Biotechnology.

Company profile comparison for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Profile Item	AVTR	REGN
Name	Avantor, Inc.	Regeneron Pharmaceuticals, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	10.48 billion USD	93.55 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 17, 2019	April 2, 1991
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

REGN

GSPC

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
Total Return (1Y)	36.41%	40.87%
Total Return (3Y, Annualized)	-5.02%	5.15%
Total Return (5Y, Annualized)	-16.62%	8.58%

Risk Profile

Drawdown History

AVTR

REGN

GSPC

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
Volatility (1Y, Annualized)	43.39%	34.08%
Beta (5Y)	0.94	0.10
Max Drawdown (5Y)	-82.42%	-59.69%
Avg. Volume (3M)	8.56M	772.95K

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and REGN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
Sharpe Ratio (1Y)	0.74	1.07
Sortino Ratio (1Y)	1.17	1.70

Profitability

ROE (TTM)

Regeneron Pharmaceuticals (REGN) at 14.95% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for REGN.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 40.46% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
ROE (TTM)	5.91%	14.95%
ROA (TTM)	2.83%	7.59%
Net Margin (TTM)	5.08%	28.51%
Operating Margin (TTM)	8.19%	40.46%
Gross Margin (TTM)	31.59%	46.73%

Growth

Revenue Growth

Regeneron Pharmaceuticals (REGN) at 0.99% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Regeneron Pharmaceuticals (REGN) at 8.19% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
Revenue Growth (YoY)	-3.41%	0.99%
Revenue Growth (3Y CAGR)	-4.46%	5.62%
EPS Growth (YoY)	-175.00%	8.19%
EPS Growth (3Y CAGR)	--	2.77%

Financial Strength

Current Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Avantor (AVTR) at 0.63 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
Current Ratio (MRQ)	1.89	3.35
Debt / Equity (MRQ)	0.63	0.08
Net Debt / EBITDA	3.40	-1.17

Dividends

Dividend Yield (TTM)

Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
Dividend Yield (TTM)	0.00%	0.41%
Dividend Payout Ratio (TTM)	0.00%	8.18%

Valuation

P/E Ratio (TTM)

Both Avantor (AVTR) at 30.94 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Regeneron Pharmaceuticals (REGN) at 5.54 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Avantor (AVTR) at 1.80 and Regeneron Pharmaceuticals (REGN) at 2.71 are valued close to their industries’ norm against book — neither stands out from peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Regeneron Pharmaceuticals (REGN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Regeneron Pharmaceuticals (REGN)
Metric	AVTR	REGN
P/E Ratio (TTM)	30.94	19.99
P/S Ratio (TTM)	1.58	5.54
P/B Ratio (MRQ)	1.80	2.71
Free Cash Flow Yield (TTM)	4.21%	2.76%